

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Hiroshi KOBAYASHI et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_1384A
Filed August 22, 2006 :
CANCER METASTASIS
INHIBITORY COMPOSITION
[Corresponding to PCT/JP2005/003130
Filed February 25, 2005]

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO: 23-0975

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application
PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No.
_____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the
above-entitled application, **or**

ATTACHMENT "C"

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/590199

IAP9 Rec'd PCT/PTO 22 AUG 2006

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☒ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☒ the concise explanation contained in the specification of the present application at pages 2-3,
 - d. ☒ the concise explanation set forth in the attached English language abstract,
 - e. ☒ the concise explanation set forth below or on a separate sheet attached to the reference:

U.S. Patent No. 6,509,445 and EP 0 890 638 correspond to WO 97/25422.

5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Hiroshi KOBAYASHI et al.

By Matthew M. Jacob
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kjf
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
August 22, 2006

10/590199
IAP0 Rec'd PCT/PTO 22 AUG 2006

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: August 22, 2006

ATTY DOCKET NO.
2006_1384ASERIAL NO.
NEWAPPLICANT
Hiroshi KOBAYASHI et al.FILING DATE
August 22, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,509,445	1/2003	Kobayashi et al.			
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AD	62-294622	12/1987	JP			Abstract
	AE	7-10773	1/1995	JP			Abstract
	AF	7-10772	1/1995	JP			Abstract
	AG	10-66572	3/1998	JP			Abstract
	AH	97/25422	7/1997	WO			
	AI	0 890 638	1/1999	EP			
	AJ	9-100298	4/1997	JP			Abstract
	AK	2000-86531	3/2000	JP			Abstract
	AL	6-145061	5/1994	JP			Abstract

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Verloes, R., et al., "PROTEOLYTIC ACTIVITY ASSOCIATED WITH TUMOUR GROWTH AND METASTASIS-INFLUENCE OF TRYPSIN INHIBITOR (SOYBEAN) ON EHRlich ASCITES TUMOR GROWTH ", Archives Internationales de Physiologie et de Biochimie, 1976, Vol. 84, No. 5, pages 1119-1120.
	AN	Jun Wu, et al., "ENHANCED VASCULAR PERMEABILITY IN SOLID TUMOR INVOLVING PEROXYNITRITE AND MATRIX METALLOPROTEINASES ", Jpn. J. Cancer Res., 2001, Vol. 92, No. 94, pages 439-451.
	AO	Tokuji Ikenaka, Protein, Nucl. Acid, Enzyme (Tokyo), "STRUCTURES AND INHIBITION MECHANISM OF LEGUM PROTEASE INHIBITORS", Vol. 27, No. 12, pages 1738-1746, (1982).
	AP	H. Kobayashi et al., "ANTI-METASTATIC THERAPY BY URINARY TRYPSIN INHIBITOR IN COMBINATION WITH AN ANTI-CANCER AGENT ", Br. J. Cancer 72: pages 1131-1137, (1995).

EXAMINER

DATE CONSIDERED